| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 36.11 | 228 |
| Intrinsic value (DCF) | 2.85 | -74 |
| Graham-Dodd Method | 0.11 | -99 |
| Graham Formula | 0.25 | -98 |
Kromek Group plc is a UK-based technology company specializing in advanced radiation detection and imaging solutions. Operating in the hardware, equipment, and parts sector, Kromek develops and manufactures high-resolution radiation detection components and devices used across medical imaging, civil nuclear, CBRNe (Chemical, Biological, Radiological, Nuclear, and explosive) security, and safety screening markets. The company's proprietary cadmium zinc telluride (CZT) and scintillator-based detectors provide critical material composition and structural data, enabling applications from cancer diagnosis to hazardous material identification. Kromek serves a global clientele, including government agencies, healthcare providers, and industrial users, through direct sales and OEM partnerships. Headquartered in Sedgefield, UK, Kromek combines scientific R&D with commercial scalability, positioning itself as a niche player in radiation detection technology. Despite its innovative product portfolio, the company operates in a capital-intensive industry with long sales cycles, impacting short-term profitability.
Kromek Group presents a high-risk, high-reward investment proposition. The company operates in specialized radiation detection markets with strong growth potential, particularly in medical imaging and nuclear security. However, its financials reveal persistent losses (net income of -£3.3M in FY2024) and negative operating cash flow (-£2.8M), raising concerns about near-term viability. The modest market cap (£37.5M) and low beta (0.539) suggest limited liquidity but lower volatility than the broader market. Investors must weigh Kromek's technological leadership in CZT detectors against its cash burn rate and £12.3M debt load. The absence of dividends reflects reinvestment needs, while global defense spending trends could drive future CBRNe demand. Suitable for speculative investors with long time horizons.
Kromek competes in the specialized radiation detection equipment market through its proprietary CZT technology, which offers superior energy resolution compared to conventional scintillator-based detectors. This technological edge provides competitive advantage in medical SPECT imaging and nuclear threat detection applications. However, the company faces challenges scaling production and achieving cost competitiveness against larger rivals. Kromek's end-to-end solutions (hardware + software) differentiate it from component suppliers, but dependence on government contracts creates revenue volatility. The company's UK base provides access to European nuclear and healthcare markets, though US competitors benefit from greater defense spending. Kromek's small scale limits R&D budgets versus multinationals, forcing niche focus areas like portable radiation detectors. Partnerships with OEMs help overcome distribution disadvantages. The competitive landscape requires balancing technological sophistication against price pressures from Asian manufacturers entering the radiation detection space.